Olaprib
Synonymous： | 4-(3-(4-(Cyclopropanecarbonyl)Piperazine-1-Carbonyl)-4-Fluorobenzyl)Phthalazin-1(2H)-One |
CAS： | 763113-22-0 |
Molecular Formula： | C24H23FN4O3 |
Molecular Weight： | 434.46 |
Appearance | White powder |
Storage | Avoid light; dry |
Category | Drugs for breast cancer and ovarian cancer |
Product introduction:
Ola Pani Ola Pani is a chemotherapeutic agent for the treatment of recurrent or advanced ovarian cancer and metastatic breast cancer in patients with specific mutations and previous history of chemotherapy. Olapani is sold under the lynparza brand in the form of oral tablets and was originally designated as maintenance therapy or monotherapy for adult patients with recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer.
Pharmacological action:
Olaparib is a new oral adenosine diphosphate ribose polymerase (PARP) inhibitor. PARP includes the most important members of three protein families: PARP1, PARP2 and parp3. PARP enzymes are involved in normal cell homeostasis, such as DNA transcription, cell cycle regulation and DNA repair. The results of olapani in vitro test showed that the drug after single drug treatment or platinum based chemical drug treatment inhibited the growth of selected tumor cell lines and reduced the tumor growth of human cancer mouse xenotransplantation model. After treatment with olaparib, the cytotoxicity and antitumor activity of BRCA deficient mouse tumor model cell lines with ovarian cancer were increased. In vitro studies also showed that olaparib induced cytotoxicity may be related to the inhibition of PARP enzyme activity and the increase of parp-dna complex formation, resulting in the destruction of cell dynamic balance and cell death.
Indications for olapani:
(1) It is suitable for the maintenance treatment of platinum sensitive recurrent ovarian cancer, whether BRCA mutation or not
(2) suitable for the treatment of HER2 negative metastatic breast cancer with BRCA mutation.
Adverse reactions:
(1) The most common adverse reactions (≥ 20%) in clinical trials were anemia, nausea, fatigue (including fatigue), vomiting, diarrhea, taste disorders, dyspepsia, headache, anorexia, nasopharyngitis / Pharyngitis / URI, cough, arthralgia / musculoskeletal pain, myalgia, back pain, dermatitis / rash and abdominal pain / discomfort.
(2) The most common laboratory abnormalities (≥ 25%) were increased creatinine, increased mean red blood cell volume, decreased hemoglobin, decreased lymphocytes, decreased absolute neutrophil count, and thrombocytopenia.
Jiangsu, China
